Supplements for perimenopause
Evidence-based picks for sleep, mood, hot flashes, bone, and the wider symptom cluster of the transition years.
The perimenopause stack — by symptom cluster
Vasomotor (hot flashes, night sweats)
MHT is the most effective intervention; non-hormonal trial-evidenced options include SSRIs/SNRIs (paroxetine, venlafaxine), gabapentin, and the newer NK3R antagonists (fezolinetant). Supplements with the cleanest signal: saffron 30 mg/day (Kashani 2018 trial showed reduction in vasomotor symptoms), and (with caveats) black cohosh — the 2012 Cochrane was inconclusive, but some standardised extracts have positive RCTs. Discuss black cohosh use with prescriber given rare hepatotoxicity reports.
Sleep and night-time symptoms
Sleep disruption in perimenopause has multiple drivers: vasomotor wake-ups, anxiety, restless legs. Magnesium glycinate 300–400 mg elemental in the evening is the core supplement. L-theanine 200 mg as needed for sleep-onset difficulty. Low-dose melatonin (0.3–0.5 mg) for sleep-phase shifts; not a primary insomnia treatment but useful adjunct. Saffron has signal for sleep-quality improvement in this cohort. If sleep is severely impaired by hot flashes, MHT or non-hormonal alternatives (fezolinetant) outperform supplements substantially.
Mood — anxiety, irritability, depressive symptoms
Saffron 30 mg/day has the cleanest single-supplement signal in perimenopausal mood symptoms — non-inferior to SSRIs in some trials, fewer side effects. Omega-3 (DHA-emphasised) at 2 g/day for depressive symptoms. Ashwagandha (KSM-66) 300–600 mg/day for anxiety component (avoid in thyroid disease). For clinical depression, this is a primary-care or psychiatry conversation — not a supplement-only approach.
Bone health — start prevention now, not later
Perimenopause is the inflection point for accelerated bone loss; bone density should be assessed if risk factors warrant (FRAX, DXA). Vitamin D3 1000–2000 IU/day to target 30–50 ng/mL. Calcium 1000–1200 mg/day total intake — diet-first, supplement only the gap, take with food. Vitamin K2 (MK-7) 100–180 mcg/day modulates calcium handling. Weight-bearing and resistance exercise outweighs all supplements for bone density.
Cardiovascular shift
Perimenopause is when LDL, blood pressure, and lipid trajectories often worsen. Omega-3 EPA/DHA 1–2 g/day for cardiovascular substrate. Mediterranean-pattern eating and exercise dominate; check BP and lipid panel at this transition.
Heavy or irregular periods
Iron status frequently drops with heavy menstrual bleeding — test ferritin and supplement if low. Don't supplement iron empirically. This is also a moment to evaluate uterine pathology (fibroids, polyps, hyperplasia) — heavy or prolonged bleeding warrants GYN evaluation.
Brain fog
Often improves with treatment of underlying sleep disruption, MHT (if appropriate), and mood. Supplement-aisle effects are modest. Omega-3 DHA, magnesium L-threonate if available, and addressing reversible deficiencies (B12, thyroid, vitamin D) are the high-utility moves. Don't chase "cognitive enhancer" products — the levers are sleep + hormones + cardiovascular health.
What to skip
- Wild yam cream as "natural progesterone" — diosgenin does not convert to progesterone in the human body; it's a synthesis precursor used industrially.
- Bioidentical hormone "compounded creams" without prescriber oversight — same risks as prescription HRT without quality control or monitoring.
- DHEA in unmonitored doses — hormonal effects with limited oversight; appropriate use under endocrinology.
- Soy isoflavones at high doses — modest hot-flash signal but quality variation across products; discuss with prescriber if hormone-sensitive history.
- "Adrenal support" / "adrenal fatigue" products — not a recognised diagnosis; products often contain stimulants and unstandardised herbs.
- Maca for everyone — promoted heavily; trial signal is modest and inconsistent.
- Routine multivitamins if diet is reasonable — not harmful but rarely the issue; targeted supplementation has higher value.
Sources
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. PMID: 35797481
- Kashani L, et al. Efficacy of Crocus sativus (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial. Arch Gynecol Obstet. 2018;297(3):717–724. PMID: 29318406
- Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev. 2012;(9):CD007244. PMID: 22972105
- Boyle NB, et al. The effects of magnesium supplementation on subjective anxiety and stress — a systematic review. Nutrients. 2017;9(5):429. PMID: 28445426
- Lopresti AL, et al. An investigation into the stress-relieving and pharmacological actions of an ashwagandha extract: a randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019;98(37):e17186. PMID: 31517876
- Avis NE, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539. PMID: 25686030